Similar articles

• Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation.

  Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engström BE, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Biller BM, Monson JP, Stewart PM, Lennernäs H, Skrtic S. Johannsson G, et al. J Clin Endocrinol Metab. 2012 Feb;97(2):473-81. doi: 10.1210/jc.2011-1926. Epub 2011 Nov 23. J Clin Endocrinol Metab. 2012. PMID: 22112807 Clinical Trial.
• Therapy of adrenal insufficiency: an update.

  Falorni A, Minarelli V, Morelli S. Falorni A, et al. Endocrine. 2013 Jun;43(3):514-28. doi: 10.1007/s12020-012-9835-4. Epub 2012 Nov 21. Endocrine. 2013. PMID: 23179775 Review.
• Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial.

  Isidori AM, Venneri MA, Graziadio C, Simeoli C, Fiore D, Hasenmajer V, Sbardella E, Gianfrilli D, Pozza C, Pasqualetti P, Morrone S, Santoni A, Naro F, Colao A, Pivonello R, Lenzi A. Isidori AM, et al. Lancet Diabetes Endocrinol. 2018 Mar;6(3):173-185. doi: 10.1016/S2213-8587(17)30398-4. Epub 2017 Dec 8. Lancet Diabetes Endocrinol. 2018. PMID: 29229498 Clinical Trial.
• Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life.

  Mongioì LM, Condorelli RA, La Vignera S, Calogero AE. Mongioì LM, et al. Endocr Connect. 2018 Jan;7(1):211-219. doi: 10.1530/EC-17-0368. Epub 2017 Dec 12. Endocr Connect. 2018. PMID: 29233815 Free PMC article.
• Secondary adrenal insufficiency: from the physiopathology to the possible role of modified-release hydrocortisone treatment.

  Paragliola RM, Corsello SM. Paragliola RM, et al. Minerva Endocrinol. 2018 Jun;43(2):183-197. doi: 10.23736/S0391-1977.17.02701-8. Epub 2017 Jul 27. Minerva Endocrinol. 2018. PMID: 28750490 Review.